Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Amortizatization of Intangibles (2019 - 2025)

Historic Amortizatization of Intangibles for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to $1.5 million.

  • IDEAYA Biosciences' Amortizatization of Intangibles fell 6899.92% to $1.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.0 million, marking a year-over-year decrease of 5706.11%. This contributed to the annual value of $10.0 million for FY2025, which is 5706.11% down from last year.
  • IDEAYA Biosciences' Amortizatization of Intangibles amounted to $1.5 million in Q4 2025, which was down 6899.92% from $2.0 million recorded in Q3 2025.
  • IDEAYA Biosciences' 5-year Amortizatization of Intangibles high stood at $6.6 million for Q2 2024, and its period low was -$469000.0 during Q4 2021.
  • In the last 5 years, IDEAYA Biosciences' Amortizatization of Intangibles had a median value of $1.8 million in 2023 and averaged $2.2 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first crashed by 898000.0% in 2021, then soared by 96483.52% in 2023.
  • Quarter analysis of 5 years shows IDEAYA Biosciences' Amortizatization of Intangibles stood at -$469000.0 in 2021, then skyrocketed by 177.61% to $364000.0 in 2022, then skyrocketed by 964.84% to $3.9 million in 2023, then increased by 26.83% to $4.9 million in 2024, then tumbled by 69.0% to $1.5 million in 2025.
  • Its Amortizatization of Intangibles stands at $1.5 million for Q4 2025, versus $2.0 million for Q3 2025 and $2.7 million for Q2 2025.